Phathom Pharmaceuticals, Inc. SEC Filings

Phathom Pharmaceuticals reported strong second-quarter 2026 results, led by product revenue of 74,274 (in thousands) for the three months ended June 30, 2026, up from 39,503 (in thousands) a year earlier. Gross profit rose to 59,178 (in thousands), and management highlighted record quarterly revenue and operating profitability when excluding non-cash stock-based compensation.

GAAP net loss narrowed to 17,582 (in thousands), or 0.21 per share, compared with 75,810 (in thousands), or 1.05 per share, in the prior-year quarter. Non-GAAP adjusted net loss was 130 (in thousands), a much smaller loss than 56,498 (in thousands) a year earlier. Cash and cash equivalents increased to 182,478 (in thousands) as of June 30, 2026. Updated 2026 guidance calls for net revenue of $310–325 million and non-GAAP operating expenses of $235–245 million, while maintaining expectations for a 55-59% gross-to-net discount and approximately 80% gross margin.

BlackRock, Inc. reported a passive ownership stake in PHARMACEUTICALS INC common stock. BlackRock and certain of its subsidiaries beneficially own 4,378,647 shares of common stock, representing 5.5% of the class.

BlackRock has sole voting power over 4,293,374 shares and sole dispositive power over 4,378,647 shares, with no shared voting or dispositive power. Various underlying clients may receive dividends or sale proceeds, but no single client holds more than five percent of PHARMACEUTICALS INC’s outstanding common shares.

Phathom Pharmaceuticals, Inc. received an updated ownership report from Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filers report beneficial ownership of 3,375,834 shares of Phathom common stock, representing 4.2% of the class. They report 0 shares with sole voting or dispositive power and 3,375,834 shares with shared voting and shared dispositive power. The filing indicates that the group now holds 5 percent or less of the outstanding common stock. A joint filing agreement dated July 17, 2026 governs this combined reporting.

Phathom Pharmaceuticals, Inc. principal accounting officer Robert Charles Breedlove reported an F-code tax-withholding disposition of 1,555 shares of common stock on July 14, 2026, at $11.035 per share, surrendering shares underlying restricted stock units to the issuer to satisfy its tax withholding obligation. After this event, he holds 59,925.0000 shares directly and 6,945.4000 shares indirectly through a 401(k) plan.

Phathom Pharmaceuticals filed an update on its drug development program, confirming it has completed enrollment in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) tablets for adults with eosinophilic esophagitis (EoE). The study has enrolled 95 patients across 41 U.S. sites, with topline results expected in the fourth quarter of 2026.

The randomized, double-blind, placebo-controlled study gives patients VOQUEZNA 20 mg or placebo once daily for 12 weeks, followed by an optional 12-week extension phase where all receive VOQUEZNA. If results are positive, Phathom plans to discuss future development in EoE with the FDA, including a potential pediatric program that could support an extension of VOQUEZNA’s regulatory exclusivity.

Phathom Pharmaceuticals director Asit Parikh reported gifting company shares rather than trading them in the market. On May 22, 2026, he made two bona fide gift transfers totaling 56,000 shares of common stock. One 28,000-share gift came from indirect holdings "by Trust" and another 28,000-share gift came from his direct holdings.

Following these gifts, Parikh’s reported indirect holdings were 148,500 shares, and his direct holdings were 24,122 shares. A footnote explains that the transferred shares went for no consideration to a trust benefiting his spouse, for which he serves as trustee, highlighting that this filing reflects estate or family planning rather than open-market buying or selling.

Phathom Pharmaceuticals director Asit Parikh reported equity compensation and an option exercise that increased his share holdings. He exercised options to acquire 17,500 shares of common stock at $4.95 per share, and the corresponding right to buy 17,500 shares was surrendered back to the company.

Parikh also received a grant of 24,122 Restricted Stock Units under the Non-Employee Director Compensation Program. These RSUs vest in full on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting, subject to continued board service. After these transactions, he holds 52,122 shares directly and 120,500 shares indirectly through a trust.

Phathom Pharmaceuticals director James N. Topper received an equity grant in the form of restricted stock units. On May 19, 2026, he was awarded 24,122 RSUs at a price of $0.00 per share under the company’s Non-Employee Director Compensation Program. These RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, as long as he continues serving on the board. Each RSU converts into one share of common stock when it vests. After this grant, Topper directly holds 66,718 common shares, alongside additional indirect holdings through several Frazier Life Sciences and related entities, some of which he reports with limited pecuniary interest.

Phathom Pharmaceuticals director Mark Stenhouse received a grant of 24,122 Restricted Stock Units (RSUs) of common stock. The award was granted on May 19, 2026 under the company’s Non-Employee Director Compensation Program and carries no cash exercise price.

All 24,122 RSUs will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as he continues serving on the board through that date. Each RSU converts into one share of common stock upon settlement, bringing his direct holdings to 54,122 shares after the grant.